HITHIUM
9.7.2024 12:43:27 CEST | Business Wire | Press release
Stationary battery manufacturer Hithium has successfully deployed the largest battery energy storage system (BESS) project in Eastern Europe to date, with a capacity of 55MWh. This solar plus storage project was realized completely by EPC company Solarpro, in Razlog, Southwestern Bulgaria, where the project is located.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240709299471/en/
Hithium BESS project in Razlog, Bulgaria (Photo: Business Wire)
The new facility officially went live in early June, with the delivery of Hithium’s 16 energy storage containers, each with a capacity of 3.44MWh, to Solarpro. Solarpro is a leading technological provider of solutions for the generation and storage of energy within whole Europe.
Hithium ∞ Block 3.44MWh container
The Hithium ∞ Block 3.44MWh container is a liquid-cooled battery storage system based on Hithium prismatic LFP BESS cells with a 280Ah capacity and a high cyclic lifetime. It is specially optimized for use in stationary battery storage systems with high standards of safety, reliability, and performance. The system’s low levelized cost of storage (LCOS), combined with excellent thermal management, improves energy throughput by ensuring optimal operating temperature and high energy density. It also integrates with a thermal management system, fire protection system, battery management system (BMS), and more.
As Kelson Li, Hithium Senior Director of Sales of DACH, Northern & Eastern Europe said: "We are honored to partner with Solarpro. By providing comprehensive technical and after-sales support throughout the project lifecycle, we aim to foster local expertise and expand the network in Europe. We believe our collaboration with Solarpro will help to accelerate the renewable energy transition and make a positive impact in the region."
Krasen Mateev, CEO of Solarpro adds: "As strategic partners in this landmark project, we are excited to collaborate with Hithium in bringing this significant BESS utility to operation. This undertaking reflects Solarpro’s dedication to advance renewable energy infrastructure in Eastern Europe, ensuring a sustainable energy future for generations to come."
Hithium’s Commitment to the European Market
Hithium is committed to fostering a stronger and more collaborative relationship within the local European market. To this end, the company has set up a regional office in Munich, Germany, offering local support and services. Furthermore, Hithium has formed strategic alliances with other industry leaders, including Scan Global Logistics, to offer unparalleled transportation services, and CarbonX, to advance the energy sector in terms of environmental responsibility and technological advancement.
About Hithium
Hithium is a leading manufacturer of top-quality stationary energy storage products for utility-scale as well as commercial and industrial applications. With more than 20GWh BESS projects shipment up to date. Hithium took the top 5 global market shares and was ranked as the Tier 1 BESS supplier. With four distinct R&D centers and multiple “intelligent” production facilities, Hithium’s innovations include groundbreaking safety improvements to its lithium-ion batteries as well as increases in lifecycle. With decades of cumulative experience in the field among its founders and senior executives, Hithium leverages its specialization in BESS to deliver partners and customers unique advances in energy storage. The company is headquartered in Xiamen, China, with locations in Shenzhen, Chongqing, Munich, Dubai, New York and California.
About Solarpro
Solarpro is a multi-technology integrator with expertise in hybrid projects that include photovoltaic (PV), wind, battery energy storage systems (BESS), and hydrogen solutions. As a leading EPC contractor with 15 years of experience and a team of over 1,000 professionals, Solarpro has designed, built, and integrated PV plants with a total capacity exceeding 7 GW. The company is a technological innovator, excelling in engineering and digitalizing renewable projects, transforming them into dispatchable and flexible assets aligned with energy market developments. Committed to sustainability, Solarpro has further developed expertise in recycling PV modules and batteries to utilize damaged or polluted land, transforming them into state-of-the-art clean energy plants.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240709299471/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
First Randomized Controlled Trial Shows Promise of a Ketogenic Diet in Psychotic Disorders8.7.2026 15:00:00 CEST | Press release
Trial reports correlations between ketone levels and cognitive and psychiatric symptoms in individuals with schizophrenia-spectrum and bipolar-1 disorders Published today in Schizophrenia Bulletin, a first-of-its-kind randomized controlled trial (RCT) from researchers at the University of California, San Francisco (UCSF), and funded in part by the National Institute of Mental Health (NIMH), adds to growing literature on the potential benefit of a ketogenic diet for treating psychotic disorders. The study, which enrolled participants with schizophrenia-spectrum or bipolar-1 disorders, demonstrated rapid metabolic improvements with a ketogenic diet compared to diet-as-usual during an initial one-month RCT open-label phase. Furthermore, those who continued with the optional four-month single-arm ketogenic diet extension saw meaningful gains across metabolic, psychiatric, and cognitive measures. This press release features multimedia. View the full release here: https://www.businesswire.co
Teamily AI Publicly Launches Human+AI Social Platform to Make Building and Growing a Company Easy for Every Team8.7.2026 15:00:00 CEST | Press release
Teamily AI (https://Teamily.ai), together with its Agentic AI Infra platform TensorOpera AI (https://TensorOpera.ai), today announced the public launch of its Human+AI social platform, a product stack that has already served more than 5 million users around the world. Starting today in Palo Alto and rolling out simultaneously across dozens of countries, this first public launch opens the full stack to everyone with a single mission: to make building and growing a company easy for every person and every team. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708584390/en/ "This is the moment we open our doors to the world," said co-founders Dr. Aiden Chaoyang He and Professor Salman Avestimehr. "We want every person and every team to be able to move from idea to product, from product to market, and from market to growth and investment, with an AI-native team by their side." At its core, Teamily AI enables humans and AI agents
Leo Cancer Care Raises $65M Series D to Scale Its Integrated Upright Cancer Care Platform8.7.2026 14:30:00 CEST | Press release
Oversubscribed round follows the world-first compact upright proton treatment at Stanford Medicine — funding a single upright platform that will span imaging and treatment across multiple radiation modalities. Leo Cancer Care, the medical technology company working to reinvent how patients are imaged and treated by designing systems around the body’s natural upright position, today announced the close of an oversubscribed $65 million Series D financing. The round was led by Silicon Valley’s Yu Galaxy and welcomes new investors including Eventide Asset Management, alongside continued support from the company’s existing investors. Leading cancer institutions are already adopting the upright approach. Stanford Medicine delivered the world’s first compact upright proton therapy treatment on 4 June 2026. Dana-Farber Cancer Institute and McLaren Health Care are among the institutions bringing the upright platform into their programmes — adoption that spans world-leading academic centers and
LUMI AI Factory Selects IQM to Deploy Advanced Quantum Computer, Accelerating Hybrid HPC and AI Development8.7.2026 14:00:00 CEST | Press release
The Halocene H4 quantum computer, named LUMI-IQ, will be delivered and installed in 2027 The system will be hosted at CSC – IT Center for Science in Finland and integrated into the LUMI AI Factory The system will provide researchers, industry innovators, and developers across Europe with a unique, advanced experimental platform where quantum computing and artificial intelligence converge The LUMI AI Factory, led by CSC – IT Center for Science, has selected IQM Quantum Computers (Nasdaq: IQMX) to deliver IQM Halocene H4, an advanced quantum computer aimed at accelerating hybrid high-performance computing, artificial intelligence, and quantum computing capabilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708006791/en/ LUMI AI Factory selects IQM to deploy advanced quantum computer, accelerating hybrid HPC and AI development IQM Halocene H4 is the first and most advanced on-premises superconducting quantum computer o
Merck Announces FDA Breakthrough Therapy Designation for Enpatoran in Lupus Patients With Active Skin Manifestations8.7.2026 14:00:00 CEST | Press release
Enpatoran could address a significant unmet need in lupus, specifically targeting cutaneous manifestations of the disease, which currently have no approved therapiesFDA's decision was supported by Phase 2 WILLOW study results, which demonstrated meaningful symptoms improvement, particularly among patients with active cutaneous manifestationsEnpatoran's potential to go beyond current treatment standards in lupus prompted FDA´s breakthrough designation, which is designed to expedite drug development and reviewNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to enpatoran for the treatment of lupus with active cutaneous manifestations. Enpatoran is an oral selective toll-like receptor (TLR) 7/8 inhibitor, designed to modulate pathways central to lupus-related inflammation. “For the 85% of lupus patients whose disease includes skin manif
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom